Clovis Oncology Inc. (NASDAQ:CLVS)’s share price was down 2.9% during mid-day trading on Monday . The stock traded as low as $16.66 and last traded at $16.91, with a volume of 426,989 shares traded. The stock had previously closed at $17.41.

Several equities analysts have recently issued reports on CLVS shares. SunTrust Banks Inc. started coverage on Clovis Oncology in a research report on Friday. They set a “buy” rating and a $25.00 target price for the company. Vetr upgraded Clovis Oncology from a “buy” rating to a “strong-buy” rating and set a $17.71 price objective for the company in a research report on Thursday, June 9th. Credit Suisse Group AG reiterated a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, July 12th. Piper Jaffray Cos. reiterated a “hold” rating and issued a $14.00 price objective on shares of Clovis Oncology in a research report on Wednesday, June 29th. Finally, Mizuho decreased their price objective on Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating for the company in a research report on Monday, April 11th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $28.89.

The company’s 50 day moving average is $14.24 and its 200-day moving average is $16.52. The stock’s market cap is $602.26 million.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same period in the prior year, the company earned ($2.10) EPS. On average, equities analysts expect that Clovis Oncology Inc. will post ($7.91) earnings per share for the current fiscal year.

Several institutional investors recently modified their holdings of CLVS. Rhumbline Advisers increased its position in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock worth $1,058,000 after buying an additional 1,880 shares during the period. California State Teachers Retirement System increased its position in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock worth $1,806,000 after buying an additional 889 shares during the period. Finally, Trexquant Investment LP bought a new position in shares of Clovis Oncology during the fourth quarter worth about $3,170,000.

Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.